Skip to main content
. Author manuscript; available in PMC: 2016 May 9.
Published in final edited form as: Ann Rheum Dis. 2012 Jan 30;71(6):1049–1054. doi: 10.1136/annrheumdis-2011-200703

Figure 4.

Figure 4

Change in proteinase-activated receptor 2 (PAR2) surface expression on peripheral blood mononuclear cells in patients with early rheumatoid arthritis (RA) but prior to treatment (pre) and 3 months after treatment with disease-modifying antirheumatic drugs (post). For both CD14 (A) and CD3 (B) cells, PAR2 expression decreased significantly (p=0.01, Mann–Whitney, n=15 and 14, respectively) following treatment.